My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
SANTOS MORIN, L; LOMBARDERO PIN, M; MATEOS EGIDO, E and VELAZ SUAREZ, MA. Adverse psychiatric effects with lorlatinib, a medicine that has not been widely used. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.1, pp.78-79. Epub Jan 18, 2021. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2020000100021.
Non-small cell lung cancer (NSCLC) is the most common cause of death worldwide. Selective molecular treatments have been an important advance in the treatment of NSCLC in certain patients whose tumors have diverse mutations such as EGFR, BRAF, ALK rearrangement or ROS.
Lorlatinib is an ALK-selective TKI that it is able to penetrate the brain and it has highly activity against ALK and ROS1 fusions, including resistance mutations. We describe the case of a woman with non-small cell lung cancer who has an adverse psychiatric effect in relation to lorlatinib.
Keywords : Lorlatinib; ROS1-rearrangement; psychiatric effect.